X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

TRVI

Closed

Trevi Therapeutics Inc

2.95
-0.15 (-4.84%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 3.1
Day's Range: 2.93 - 3.1
Send
When Written:
 
1.83
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company that is focused on developing therapies for patients suffering from rare neurological disorders. The company's lead product candidate, Nalbuphine ER, is a long-acting oral formulation of nalbuphine, a potent opioid analgesic that has been used for decades in the management of acute and chronic pain.

Trevi Therapeutics was founded in 2011 and is headquartered in New Haven, Connecticut. The company is led by a team of experienced industry executives and has partnerships with leading academic institutions and research organizations.

In addition to Nalbuphine ER, Trevi Therapeutics is also exploring the potential of other compounds in its pipeline for the treatment of various neurological disorders. These include TRV250, a novel delta opioid receptor agonist for the treatment of acute migraine, and TRV734, a G protein-biased mu opioid receptor agonist for the treatment of chronic pain.

Trevi Therapeutics has received funding from a variety of sources, including venture capital firms and government agencies. The company went public in 2019 and is listed on the NASDAQ stock exchange under the ticker symbol TRVI.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:18.227.13.171
X